Liu, Shujing

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersExtracellular vesicles in disease

Cited by 2,813

Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells

Yang, R., Zheng, Y., Burrows, M., Liu, S., Wei, Z., Nace, A., Guo, W., Kumar, S., Cotsarelis, G., & Xu, X. (2014) · Nature Communications

Hair Growth and DisordersPluripotent Stem Cells Research

Cited by 125

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma

Sharma, G., Ojha, R., Noguera-Ortega, E., Rebecca, V. W., Attanasio, J., Liu, S., Piao, S., Lee, J. J., Nicastri, M. C., Harper, S. L., et al. (2020) · JCI Insight

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 80

Loss of microRNA-205 expression is associated with melanoma progression

Liu, S., Tetzlaff, M. T., Liu, A., Liegl-Atzwanger, B., Guo, J., & Xu, X. (2012) · Laboratory Investigation

MicroRNA in disease regulationCancer-related molecular mechanisms research

Cited by 74

miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

Liu, S., Tetzlaff, M. T., Wang, T., Yang, R., Xie, L., Zhang, G., Krepler, C., Xiao, M., Beqiri, M., Xu, W., et al. (2015) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysMicroRNA in disease regulation

Cited by 54

Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients

Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 40